JAMA 282(14):1344–1352PubMedCrossRef 13 Reginster J, Minne HW, S

JAMA 282(14):1344–1352PubMedCrossRef 13. Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group. Osteoporos Int 11:83–91PubMedCrossRef 14. McClung MR, Geusens P, Miller this website PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340PubMedCrossRef 15. Masud T, McClung M, Geusens P (2009) Reducing

hip fracture risk with risedronate in elderly women with established osteoporosis. Clin Interv Aging 4:445–449PubMedCrossRef 16. MacLean C, Newberry S, Maglione M et al (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med Sotrastaurin datasheet 148:197–213PubMed

17. Yoshihiro S, Tomohiro K, Kei S et al (2005) The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease. Arch Inter Med 165:1737–1742CrossRef 18. Yoshihiro S, Jun I, Tomohiro K et al (2005) Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Inter Med 165:1743–1748CrossRef 19. Investigational Committee for Osteoporosis Diagnosis Standard, Japanese Society for Bone and Mineral Research (2001) Diagnosis standard for primary osteoporosis (2000 revised edition). Fluorometholone Acetate J Jpn Soc Bone Miner Res 8:76–82

20. De Laet C, Kanis JA, Odén A et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330–1338PubMedCrossRef 21. Chevalley T, Guilley E, Herrmann FR et al (2007) Incidence of hip fracture over a 10-year period (1991-2000): reversal of a secular trend. Bone 40:1284–1289PubMedCrossRef 22. Melton LJ 3rd, Kearns AE, Atkinson EJ (2009) Secular trends in hip fracture incidence and recurrence. Osteoporos Int 20:687–694PubMedCrossRef 23. Hagino H, Furukawa K, Fujiwara S et al (2009) Recent trends in the incidence and lifetime risk of hip fracture in Tottori, Japan. Osteoporos Int 20:543–548PubMedCrossRef 24. Lyles KW, Colón-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRef 25. Peter CP, Kindt MV, Majka JA (1998) Comparative study of potential for bisphosphonates to damage gastric mucosa of rats. Dig Dis Sci 43:1009–1015PubMedCrossRef 26. Kushida K, Kishimoto H et al (2002) Efficacy and safety of long-term treatment with risedronate in patients with osteoporosis and osteopenia. Osteoporos Jpn 10:85–97, in Japanese 27. Hooven FH, Adachi JD, Adami S et al (2009) The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design.

Comments are closed.